Konstantinos N. Kontogiannopoulos

Dr. Konstantinos N. Kontogiannopoulos

Hellenic Agricultural Organisation Dimitra, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Konstantinos N. KontogiannopoulosKonstantinos N. Kontogiannopoulos
Konstantinos N. Kontogiannopoulos
AAAndreana N. Assimopoulou
Andreana N. Assimopoulou
Ioannis TsivintzelisIoannis Tsivintzelis
Ioannis Tsivintzelis
CPCostas Panayiotou
Costas Panayiotou
VPVassilios P. Papageorgiou
Vassilios P. Papageorgiou

22 February 2022 in Polymers
Verified
Journal Article
Open access
PDF file
Afroditi KapouraniAfroditi Kapourani
Afroditi Kapourani
Konstantinos N. KontogiannopoulosKonstantinos N. Kontogiannopoulos
Konstantinos N. Kontogiannopoulos
AMAlexandra Eleftheria Manioudaki
Alexandra Eleftheria Manioudaki
APATHANASIOS POULOPOULOS
ATHANASIOS POULOPOULOS
LTLazaros Tsalikis
Lazaros Tsalikis
Panagiotis BarmpalexisPanagiotis Barmpalexis
Panagiotis Barmpalexis
The medical term xerostomia refers to the subjective sensation of oral dryness. The etiology seems to be multifactorial with the most frequently reported causes being the use of xerostomic medications, neck and head radiation, and systematic diseases (such as Sjögren’s syndrome). Xerostomia is associated with an increased incidence of dental caries, oral fungal infections, and difficulties in speaking and chewing/swallowing, which ultimately affect the oral health-related quality of life. The development of successful management schemes is regarded as a highly challenging project due to the complexity of saliva. This is why, in spite of the fact that there are therapeutic options aiming to improve salivary function, most management approaches are alleviation-oriented. In any case, polymers are an integral part of the various formulations used in every current treatment approach, especially in the saliva substitutes, due to their function as thickening and lubricating agents or, in the case of mucoadhesive polymers, their ability to prolong the treatment effect. In this context, the present review aims to scrutinize the literature and presents an overview of the role of various polymers (or copolymers) on either already commercially available formulations or novel drug delivery systems currently under research and development.

7 September 2022 in Energies
Verified
Journal Article
Open access
PDF file
GMGeorgia-Christina Mitraka
Georgia-Christina Mitraka
Konstantinos N. KontogiannopoulosKonstantinos N. Kontogiannopoulos
Konstantinos N. Kontogiannopoulos
Maria BatsioulaMaria Batsioula
Maria Batsioula
Georgios F. BaniasGeorgios F. Banias
Georgios F. Banias
Anastasios ZouboulisAnastasios Zouboulis
Anastasios Zouboulis
Panagiotis Panagiotis G. KougiasPanagiotis Panagiotis G. Kougias
Panagiotis Panagiotis G. Kougias
The treatment of municipal wastewater is considered a cornerstone for the protection of public health and environment. However, a major issue derived from this process is the large quantities of produced sewage sludge. Although anaerobic digestion is a widely applied method in Wastewater Treatment Plants (WWTPs) aiming to stabilize the sludge and to recover energy in the form of methane, it is usually limited due to the reduced decomposition efficiency and slow biodegradation rate of this recalcitrant substrate. For this reason, various pretreatment methods have been proposed aiming to modify the sludge structure, solubilize the organic matter, and decrease the crystallinity of sludge so as to accelerate hydrolysis and consequently enhance methane production. The current research is a comprehensive collection of recent advances in pretreatment technologies that can be potentially applied in wastewater treatment facilities. The critical review analysis presented herein reveals the several advantages and drawbacks, as well as the technical opportunities of the pretreatment methods and provides an assessment of their feasibility/applicability from an energetic, environmental, and economic point of view.

1 June 2016 in Separation and Purification Technology
Verified
Journal Article
Closed access
Konstantinos N. KontogiannopoulosKonstantinos N. Kontogiannopoulos
Konstantinos N. Kontogiannopoulos
Sotiris I. PatsiosSotiris I. Patsios
Sotiris I. Patsios
AKAnastasios J. Karabelas
Anastasios J. Karabelas

18 June 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Afroditi KapouraniAfroditi Kapourani
Afroditi Kapourani
Konstantinos N. KontogiannopoulosKonstantinos N. Kontogiannopoulos
Konstantinos N. Kontogiannopoulos
Panagiotis BarmpalexisPanagiotis Barmpalexis
Panagiotis Barmpalexis
Xerostomia is linked to an increased risk of dental caries, oral fungal infections, and speaking/swallowing difficulties, factors that may significantly degrade patients’ life, socially- or emotionally-wise. Consequently, there is an increasing interest in developing management approaches for confronting this oral condition, at which pilocarpine, a parasympathomimetic agent, plays a vital role. Although the therapeutic effects of orally administrated pilocarpine on the salivary gland flow and the symptoms of xerostomia have been proved by numerous studies, the systemic administration of this drug is affiliated with various adverse effects. Some of the typical adverse effects include sweating, nausea, vomiting, diarrhea, rhinitis, dizziness and increased urinary frequency. In this vein, new strategies to develop novel and effective dosage forms for topical (i.e., in the oral cavity) pilocarpine administration, in order for the salivary flow to be enhanced with minimal systemic manifestations, have emerged. Therefore, the purpose of the current review is to survey the literature concerning the performance of topical pilocarpine delivery systems. According to the findings, the topical delivery of pilocarpine can be regarded as the equivalent to systemic delivery of the drug, efficacy-wise, but with improved patient tolerance and less adverse effects.

11 February 2022 in Chemosphere
Verified
Journal Article
Closed access
CAChrysa Anagnostopoulou
Chrysa Anagnostopoulou
Konstantinos N. KontogiannopoulosKonstantinos N. Kontogiannopoulos
Konstantinos N. Kontogiannopoulos
MGMaria Gaspari
Maria Gaspari
MMMaria Silvia Morlino
Maria Silvia Morlino
AAAndreana N. Assimopoulou
Andreana N. Assimopoulou
Panagiotis Panagiotis G. KougiasPanagiotis Panagiotis G. Kougias
Panagiotis Panagiotis G. Kougias